These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9207934)

  • 21. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation.
    Loher F; Bauer C; Landauer N; Schmall K; Siegmund B; Lehr HA; Dauer M; Schoenharting M; Endres S; Eigler A
    J Pharmacol Exp Ther; 2004 Feb; 308(2):583-90. PubMed ID: 14610233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
    Heinze-Krauss I; Angehrn P; Charnas RL; Gubernator K; Gutknecht EM; Hubschwerlen C; Kania M; Oefner C; Page MG; Sogabe S; Specklin JL; Winkler F
    J Med Chem; 1998 Oct; 41(21):3961-71. PubMed ID: 9767633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
    Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
    J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake.
    Moore MC; Dicostanzo CA; Smith MS; Farmer B; Rodewald TD; Neal DW; Williams PE; Cherrington AD
    Am J Physiol Endocrinol Metab; 2008 Apr; 294(4):E768-77. PubMed ID: 18212022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleophilic opening of epoxyazepanes: expanding the family of polyhydroxyazepane-based glycosidase inhibitors.
    Li H; Schütz C; Favre S; Zhang Y; Vogel P; Sinaÿ P; Blériot Y
    Org Biomol Chem; 2006 May; 4(9):1653-62. PubMed ID: 16633556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and target identification of hymenialdisine analogs.
    Wan Y; Hur W; Cho CY; Liu Y; Adrian FJ; Lozach O; Bach S; Mayer T; Fabbro D; Meijer L; Gray NS
    Chem Biol; 2004 Feb; 11(2):247-59. PubMed ID: 15123286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of a macrocyclic inhibitor for peptide deformylase.
    Hu X; Nguyen KT; Verlinde CL; Hol WG; Pei D
    J Med Chem; 2003 Aug; 46(18):3771-4. PubMed ID: 12930137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.
    Hom RK; Fang LY; Mamo S; Tung JS; Guinn AC; Walker DE; Davis DL; Gailunas AF; Thorsett ED; Sinha S; Knops JE; Jewett NE; Anderson JP; John V
    J Med Chem; 2003 May; 46(10):1799-802. PubMed ID: 12723942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors.
    Nagase T; Takahashi T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N
    J Med Chem; 2009 Jul; 52(14):4111-4. PubMed ID: 19522500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.
    Sorensen B; Winn M; Rohde J; Shuai Q; Wang J; Fung S; Monzon K; Chiou W; Stolarik D; Imade H; Pan L; Deng X; Chovan L; Longenecker K; Judge R; Qin W; Brune M; Camp H; Frevert EU; Jacobson P; Link JT
    Bioorg Med Chem Lett; 2007 Jan; 17(2):527-32. PubMed ID: 17070044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling caspase-1 inhibition: Implications for catalytic mechanism and drug design.
    Ramos-Guzmán CA; Zinovjev K; Tuñón I
    Eur J Med Chem; 2019 May; 169():159-167. PubMed ID: 30875506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
    Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
    Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of specific interleukin-1beta-converting enzyme inhibitor on ischemic acute renal failure in murine models.
    Liu HF; Liang D; Wang LM; Zhou N; Yao CW; Hong T; Tang DS; Chen XW
    Acta Pharmacol Sin; 2005 Nov; 26(11):1345-51. PubMed ID: 16225757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Poli ANR; Tietjen I; Nandwana NK; Cassel J; Messick TE; Register ET; Keeney F; Rajaiah R; Verma AK; Pandey K; Acharya A; Byrareddy SN; Montaner LJ; Salvino JM
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0056224. PubMed ID: 39225484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small Molecule Active Site Directed Tools for Studying Human Caspases.
    Poreba M; Szalek A; Kasperkiewicz P; Rut W; Salvesen GS; Drag M
    Chem Rev; 2015 Nov; 115(22):12546-629. PubMed ID: 26551511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.